Print

Purpose

IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.

Condition

Eligibility

Eligible Ages
Under 48 Hours
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Gestational age at birth of 23 weeks+0 days to 32 weeks+0 days - Birth weight 500-1500g - ≤ 48 hours of age - Written informed consent from the subject´s legally authorized representative (LAR)

Exclusion Criteria

  • Participation in any other interventional clinical trial - Infants in extremis to whom no further intensive care is offered by attending neonatologist - Infants with, or at a high probability for, early onset sepsis - Infants with recognized chromosomal anomalies - Congenital or acquired gastrointestinal disease - Earlier or planned administration of formulas, foods or supplements that contain added live bacteria - Infants with known positive maternal HIV status

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
IBP-9414
  • Drug: IBP-9414
    Oral suspension
Placebo Comparator
Placebo
  • Drug: Placebo
    Sterile water

More Details

Status
Active, not recruiting
Sponsor
Infant Bacterial Therapeutics

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.